KR20160100302A - 라퀴니모드를 사용하는 녹내장의 치료 - Google Patents

라퀴니모드를 사용하는 녹내장의 치료 Download PDF

Info

Publication number
KR20160100302A
KR20160100302A KR1020167015972A KR20167015972A KR20160100302A KR 20160100302 A KR20160100302 A KR 20160100302A KR 1020167015972 A KR1020167015972 A KR 1020167015972A KR 20167015972 A KR20167015972 A KR 20167015972A KR 20160100302 A KR20160100302 A KR 20160100302A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
package
mode
day
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167015972A
Other languages
English (en)
Korean (ko)
Inventor
론 노이만
레비탈 에치오니
Original Assignee
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 테바 파마슈티컬 인더스트리즈 리미티드
Publication of KR20160100302A publication Critical patent/KR20160100302A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D1/00—Rigid or semi-rigid containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material or by deep-drawing operations performed on sheet material
    • B65D1/02—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents
    • B65D1/0207—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents characterised by material, e.g. composition, physical features
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y10S514/913—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167015972A 2013-11-15 2014-11-13 라퀴니모드를 사용하는 녹내장의 치료 Withdrawn KR20160100302A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904962P 2013-11-15 2013-11-15
US61/904,962 2013-11-15
PCT/US2014/065497 WO2015073697A1 (en) 2013-11-15 2014-11-13 Treatment of glaucoma using laquinimod

Publications (1)

Publication Number Publication Date
KR20160100302A true KR20160100302A (ko) 2016-08-23

Family

ID=53058023

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167015972A Withdrawn KR20160100302A (ko) 2013-11-15 2014-11-13 라퀴니모드를 사용하는 녹내장의 치료

Country Status (12)

Country Link
US (6) US20150141458A1 (enExample)
EP (1) EP3068395A4 (enExample)
JP (1) JP2016537364A (enExample)
KR (1) KR20160100302A (enExample)
CN (1) CN105960238A (enExample)
AU (1) AU2014348620A1 (enExample)
CA (1) CA2930113A1 (enExample)
EA (1) EA201690903A1 (enExample)
HK (1) HK1225971A1 (enExample)
IL (1) IL245373A0 (enExample)
MX (1) MX2016006256A (enExample)
WO (1) WO2015073697A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019182814A (ja) * 2018-04-17 2019-10-24 国立大学法人九州大学 生体リズム調整剤及び生体リズム調整用医薬組成物
MX2022006439A (es) * 2019-12-19 2022-07-19 Active Biotech Ab Compuestos para el tratamiento de enfermedades oculares asociadas con la vascularizacion excesiva.
EP3888650A1 (en) 2020-03-30 2021-10-06 Universität Regensburg Biochanin a diacetate for treatment of best1-related retinopathies
KR20230165260A (ko) 2021-04-01 2023-12-05 액티브 바이오테크 에이비 안구용 라퀴니모드 제형
CN119523881A (zh) * 2024-04-28 2025-02-28 中国人民解放军海军军医大学第二附属医院 一种s100a9抑制剂凝胶剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754712B1 (fr) * 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
US8039507B2 (en) * 2005-06-29 2011-10-18 Allergan, Inc. Therapeutic substituted gamma lactams
EP2318371A2 (en) * 2008-07-01 2011-05-11 Actavis Group PTC EHF Novel solid state forms of laquinimod and its sodium salt
RS54707B1 (sr) * 2009-07-30 2016-08-31 Teva Pharmaceutical Industries Ltd. Tretman kronove bolesti lakvinimodom
PL3064206T3 (pl) * 2009-08-10 2020-02-28 Active Biotech Ab Leczenie choroby Huntingtona z zastosowaniem lakwinimodu
EP2736335A4 (en) * 2011-07-28 2015-01-07 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS USING A COMBINATION OF LAQUINIMOD AND GLATIRAMERATE ACETATE
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病

Also Published As

Publication number Publication date
EP3068395A1 (en) 2016-09-21
US20170128436A1 (en) 2017-05-11
AU2014348620A1 (en) 2016-06-16
IL245373A0 (en) 2016-06-30
US20170368054A1 (en) 2017-12-28
EP3068395A4 (en) 2017-07-12
CA2930113A1 (en) 2015-05-21
CN105960238A (zh) 2016-09-21
US20170266179A1 (en) 2017-09-21
JP2016537364A (ja) 2016-12-01
EA201690903A1 (ru) 2016-10-31
HK1225971A1 (zh) 2017-09-22
US20150141458A1 (en) 2015-05-21
US20180140593A1 (en) 2018-05-24
WO2015073697A1 (en) 2015-05-21
US20170027927A1 (en) 2017-02-02
MX2016006256A (es) 2016-09-07

Similar Documents

Publication Publication Date Title
TWI714596B (zh) 用於治療翼狀胬肉之組合物及方法
CN107362157B (zh) 用于医学和兽医学的眼科药物组合物
Flach et al. Quantitative assessment of postsurgical breakdown of the blood-aqueous barrier following administration of 0.5% ketorolac tromethamine solution: a double-masked, paired comparison with vehicle-placebo solution study
PT1789433E (pt) Métodos de tratamento de vermelhidão cutânea usando agonistas selectivos do receptor adrenérgico alfa-2
US20180140593A1 (en) Treatment of Glaucoma Using Laquinimod
CA3171479A1 (en) Compositions comprising axitinib and methods of treating ocular disorders
KR20150032552A (ko) 치료 제제 및 치료 방법
US20210267999A1 (en) Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration
ES2860767T3 (es) Mirabegrón para el tratamiento de enfermedades retinianas
BRPI0620080A2 (pt) formulações tópicas de mecamilamina para adminstração ocular e usos das mesma
McCLANAHAN et al. Ocular manifestations of chronic phenothiazine derivative administration
RU2528912C1 (ru) Глазные капли на основе композиции фармацевтически приемлемой аддитивной соли кислоты и метилэтилпиридинола, содержащие композицию витаминов группы в
JP2003512324A (ja) 眼疾患の処置のためのリバスチグミン
WO2024102458A1 (en) Methods of using trazodone to reverse the effects of 5-ht2a receptor agonists
JP6153838B2 (ja) 血管透過性抑制剤
KR102879076B1 (ko) Sglt-2 억제제를 포함하는 당뇨병성 안질환 예방 또는 치료용 약학적 조성물
CN116270442B (zh) 一种用于矫正近距离视力的眼用制剂
KR102228401B1 (ko) 유리체 절제술 및 안구 내 mnu 주입과 제거를 이용한 망막 변성 동물 모델의 제조방법 및 이를 이용한 망막 변성 동물 모델
KR20230136579A (ko) 안구건조증 치료를 위한 레코플라본 함유 점안 조성물 및 이의 제조방법
WO2022251543A1 (en) Use of complement factor d inhibitor for treatment of geographic atrophy secondary to age-related macular degeneration
KR20230021613A (ko) 안구건조증 치료를 위한 레코플라본 함유 점안 조성물 및 이의 제조방법
Zhang et al. Nonprescribed Systemic Drugs and Therapies
KR20240102577A (ko) 당뇨망막병증의 예방 및 치료를 위한 다파글리플로진을 함유하는 약제학적 조성물
ES2770698T3 (es) Utilización de hidroxicarbamida para prevenir la no perfusión retiniana
WO2025162430A1 (zh) 一种药物联用及其在预防或治疗神经退行性疾病中的用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000